Clinical Psychopharmacology and Neuroscience

Korean College of Neuropsychopharmacology (대한정신약물학회)
권호 표지
DOI QR코드

DOI QR Code

Korean Medication Algorithm Project for Bipolar Disorder 2018 (KMAP-BP 2018): Fourth Revision

  • Woo, Young Sup (Department of Psychiatry, College of Medicine, The Catholic University of Korea) ;
  • Bahk, Won-Myong (Department of Psychiatry, College of Medicine, The Catholic University of Korea) ;
  • Lee, Jung Goo (Department of Psychiatry, Inje University Haeundae Paik Hospital, Inje University College of Medicine and Paik Institute for Clinical Research) ;
  • Jeong, Jong-Hyun (Department of Psychiatry, College of Medicine, The Catholic University of Korea) ;
  • Kim, Moon-Doo (Department of Psychiatry, Jeju National University Hospital) ;
  • Sohn, InKi (Department of Psychiatry, Keyo Hospital, Keyo Medical Foundation) ;
  • Shim, Se-Hoon (Department of Psychiatry, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine) ;
  • Jon, Duk-In (Department of Psychiatry, Hallym University Sacred Heart Hospital, Hallym University College of Medicine) ;
  • Seo, Jeong Seok (Department of Psychiatry, School of Medicine, Konkuk University) ;
  • Min, Kyung Joon (Department of Psychiatry, Chung-Ang University College of Medicine) ;
  • Kim, Won (Department of Psychiatry, Inje University Seoul Paik Hospital, Inje University College of Medicine) ;
  • Song, Hoo-Rim (Department of Psychiatry, Myongji Hospital) ;
  • Yoon, Bo-Hyun (Department of Psychiatry, Naju National Hospital)
  • Received : 2018.05.09
  • Accepted : 2018.05.16
  • Published : 2018.11.30
⟨ Previous Next ⟩

Abstract

Objective: The Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP) was first published in 2002 through an expert consensus of opinion, and updated in 2006, 2010, and 2014. This study constitutes the fourth revision of the KMAP-BP. Methods: A 50-item questionnaire was used to obtain the consensus of experts regarding pharmacological treatment strategies for various phases of adult bipolar disorder and six items for pediatric bipolar disorder. The review committee included 84 Korean psychiatrists and 43 child and adolescent psychiatry experts. Results: The preferred first-step strategies for acute mania were the combination of a mood stabilizer (MS) and an atypical antipsychotic (AAP), MS monotherapy, and AAP monotherapy. A combination of a MS and an AAP, and AAP monotherapy were preferred for psychotic mania. The first-step strategies for mild to moderate bipolar depression were monotherapy with MS, AAP, or lamotrigine (LMT), and the combination of a MS and an AAP or LMT, or a combination of an AAP and LMT. The combination of two among a MS, AAP, and LMT were preferred for non-psychotic severe depression. A combination of a MS and an AAP or the combination of an AAP with an antidepressant or LMT were the first-line options for psychotic severe depression. Conclusion: The recommendations of the KMAP-BP 2018 have changed from the previous version by reflecting recent developments in pharmacotherapy for bipolar disorder. KMAP-BP 2018 provides clinicians with a wealth of information regarding appropriate strategies for treating patients with bipolar disorder.

Keywords

References

  1. Parker GB, Graham RK, Tavella G. Is there consensus across international evidence-based guidelines for the management of bipolar disorder? Acta Psychiatr Scand 2017;135:515-526. https://doi.org/10.1111/acps.12717
  2. Bahk WM, Shin YC, Jon DI, Yoon BH, Kim DJ, Ahn YM, et al. Korean Medication Algorithm for Bipolar Disorder (I). Korean J Psychopharmacol 2002;13:205-221.
  3. Kim CH, Min KJ, Shin YC, Yun BH, Cho HS, Jon DI, et al. Feasibility of Korean Medication Algorithm for Bipolar Disorder (I): Global assessment. Korean J Psychopharmacol 2005;16:225-233.
  4. Shin YC, Bahk WM, Kim CH, Min KJ, Yun BH, Cho HS, et al. Feasibility of Korean Medication Algorithm for Bipolar Disorder (II): Choice of medications. Korean J Psychopharmacol 2005;16:285-291.
  5. Jon DI, Bahk WM, Shin YC, Kim CH, Min KJ, Yun BH, et al. Feasibility of Korean Medication Algorithm for Bipolar Disorder (III): Treatment response and tolerability. Korean J Psychopharmacol 2005;16:292-300.
  6. Seo JS, Bahk WM, Wang HR, Woo YS, Park YM, Jeong JH, et al. Korean Medication Algorithm for Depressive Disorders 2017: third revision. Clin Psychopharmacol Neurosci 2018;16:67-87. https://doi.org/10.9758/cpn.2018.16.1.67
  7. Wang HR, Bahk WM, Seo JS, Woo YS, Park YM, Jeong JH, et al. Korean Medication Algorithm for Depressive Disorder: Comparisons with other treatment guidelines. Clin Psychopharmacol Neurosci 2017;15:199-209. https://doi.org/10.9758/cpn.2017.15.3.199
  8. Jon DI, Bahk WM, Yoon BH, Shin YC, Cho HS, Lee E, et al. Revised Korean Medication Algorithm for Bipolar Disorder. World J Biol Psychiatry 2009;10:846-855. https://doi.org/10.1080/15622970802144865
  9. Shin YC, Min KJ, Yoon BH, Kim W, Jon DI, Seo JS, et al. Korean Medication Algorithm for Bipolar Disorder: second revision. Asia Pac Psychiatry 2013;5:301-308. https://doi.org/10.1111/appy.12062
  10. Woo YS, Lee JG, Jeong JH, Kim MD, Sohn I, Shim SH, et al. Korean Medication Algorithm Project for Bipolar Disorder: third revision. Neuropsychiatr Dis Treat 2015;11:493-506.
  11. American Psychiatric Association; DSM-5 Task Force. Diagnostic and statistical manual of mental disorders, 5th ed: DSM-5. Arlington, VA:American Psychiatric Association;2013.
  12. Sachs GS, Printz DJ, Kahn DA, Carpenter D, Docherty JP. The Expert Consensus Guideline Series: medication treatment of bipolar disorder 2000. Postgrad Med 2000;Spec No:1-104.
  13. Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Moller HJ, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry 2009;10:85-116. https://doi.org/10.1080/15622970902823202
  14. Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord 2013;15:1-44.
  15. Lin D, Mok H, Yatham LN. Polytherapy in bipolar disorder. CNS Drugs 2006;20:29-42. https://doi.org/10.2165/00023210-200620010-00003
  16. Ketter TA. Monotherapy versus combined treatment with second- generation antipsychotics in bipolar disorder. J Clin Psychiatry 2008;69 Suppl 5:9-15. https://doi.org/10.4088/JCP.0308e09
  17. Bourin MS, Severus E, Schronen JP, Gass P, Szamosi J, Eriksson H, et al. Lithium as add-on to quetiapine XR in adult patients with acute mania: a 6-week, multicenter, double-blind, randomized, placebo-controlled study. Int J Bipolar Disord 2014;2:14. https://doi.org/10.1186/s40345-014-0014-9
  18. Xu L, Lu Y, Yang Y, Zheng Y, Chen F, Lin Z. Olanzapine-valproate combination versus olanzapine or valproate monotherapy in the treatment of bipolar I mania: a randomized controlled study in a Chinese population group. Neuropsychiatr Dis Treat 2015;11:1265-1271.
  19. Ogawa Y, Tajika A, Takeshima N, Hayasaka Y, Furukawa TA. Mood stabilizers and antipsychotics for acute mania: a systematic review and meta-analysis of combination/augmentation therapy versus monotherapy. CNS Drugs 2014;28:989-1003. https://doi.org/10.1007/s40263-014-0197-8
  20. Levin JB, Krivenko A, Howland M, Schlachet R, Sajatovic M. Medication adherence in patients with bipolar disorder: a comprehensive review. CNS Drugs 2016;30:819-835. https://doi.org/10.1007/s40263-016-0368-x
  21. Leclerc E, Mansur RB, Brietzke E. Determinants of adherence to treatment in bipolar disorder: a comprehensive review. J Affect Disord 2013;149:247-252. https://doi.org/10.1016/j.jad.2013.01.036
  22. Galling B, Garcia MA, Osuchukwu U, Hagi K, Correll CU. Safety and tolerability of antipsychotic-mood stabilizer co-treatment in the management of acute bipolar disorder: results from a systematic review and exploratory meta-analysis. Expert Opin Drug Saf 2015;14:1181-1199. https://doi.org/10.1517/14740338.2015.1053457
  23. Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet 2011;378:1306-1315. https://doi.org/10.1016/S0140-6736(11)60873-8
  24. Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 2018;20:97-170. https://doi.org/10.1111/bdi.12609
  25. Fountoulakis KN, Grunze H, Vieta E, Young A, Yatham L, Blier P, et al. The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 3: the clinical guidelines. Int J Neuropsychopharmacol 2017;20:180-195.
  26. Lindstrom L, Lindstrom E, Nilsson M, Hoistad M. Maintenance therapy with second generation antipsychotics for bipolar disorder - A systematic review and meta-analysis. J Affect Disord 2017;213:138-150. https://doi.org/10.1016/j.jad.2017.02.012
  27. Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Moller HJ, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry 2013;14:154-219. https://doi.org/10.3109/15622975.2013.770551
  28. Calabrese JR, Huffman RF, White RL, Edwards S, Thompson TR, Ascher JA, et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disord 2008;10:323-333. https://doi.org/10.1111/j.1399-5618.2007.00500.x
  29. Unholzer S, Haen E. Retrospective analysis of therapeutic drug monitoring data for treatment of bipolar disorder with Lamotrigine. Pharmacopsychiatry 2015;48:296. https://doi.org/10.1055/s-0035-1565223
  30. Solmi M, Veronese N, Zaninotto L, van der Loos ML, Gao K, Schaffer A, et al. Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials. CNS Spectr 2016;21:403-418. https://doi.org/10.1017/S1092852916000523
  31. National Collaborating Centre for Mental Health (UK). Bipolar disorder: the assessment and management of bipolar disorder in adults, children and young people in primary and secondary care, revised version. Leicester (UK):British Psychological Society;2014.
  32. Goodwin GM, Haddad PM, Ferrier IN, Aronson JK, Barnes T, Cipriani A, et al. Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2016;30:495-553. https://doi.org/10.1177/0269881116636545
  33. Vieta E. Antidepressants in bipolar I disorder: never as monotherapy. Am J Psychiatry 2014;171:1023-1026. https://doi.org/10.1176/appi.ajp.2014.14070826
  34. Shim IH, Woo YS, Wang HR, Bahk WM. Predictors of a shorter time to hospitalization in patients with bipolar disorder: Medication during the acute and maintenance phases and other clinical factors. Clin Psychopharmacol Neurosci 2017;15:248-255. https://doi.org/10.9758/cpn.2017.15.3.248
  35. Vazquez GH, Tondo L, Undurraga J, Baldessarini RJ. Overview of antidepressant treatment of bipolar depression. Int J Neuropsychopharmacol 2013;16:1673-1685. https://doi.org/10.1017/S1461145713000023
  36. Fountoulakis KN, Yatham L, Grunze H, Vieta E, Young A, Blier P, et al. The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, grading of the evidence, and a precise algorithm. Int J Neuropsychopharmacol 2017;20:121-179.
  37. Cruz N, Sanchez-Moreno J, Torres F, Goikolea JM, Valenti M, Vieta E. Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. Int J Neuropsychopharmacol 2010;13:5-14. https://doi.org/10.1017/S1461145709990344
  38. Sanford M, Keating GM. Quetiapine: a review of its use in the management of bipolar depression. CNS Drugs 2012;26:435-460. https://doi.org/10.2165/11203840-000000000-00000
  39. Yatham LN. A clinical review of Aripiprazole in bipolar depression and maintenance therapy of bipolar disorder. J Affect Disord 2011;128 Suppl 1:S21-S28. https://doi.org/10.1016/S0165-0327(11)70005-2
  40. Thase ME, Bowden CL, Nashat M, Eudicone JM, Marcus R, McQuade RD, et al. Aripiprazole in bipolar depression: a pooled, post-hoc analysis by severity of core depressive symptoms. Int J Psychiatry Clin Pract 2012;16:121-131. https://doi.org/10.3109/13651501.2011.632680
  41. Fountoulakis KN, Vieta E, Schmidt F. Aripiprazole monotherapy in the treatment of bipolar disorder: a meta-analysis. J Affect Disord 2011;133:361-370. https://doi.org/10.1016/j.jad.2010.10.018
  42. Woo YS, Shim IH, Lee SY, Lee DB, Kim MD, Jung YE, et al. Dose trends of aripiprazole from 2004 to 2014 in psychiatric inpatients in Korea. Clin Psychopharmacol Neurosci 2017;15:177-180. https://doi.org/10.9758/cpn.2017.15.2.177
  43. Muneer A. Mixed states in bipolar disorder: etiology, pathogenesis and treatment. Chonnam Med J 2017;53:1-13. https://doi.org/10.4068/cmj.2017.53.1.1
  44. Weisler RH, Hirschfeld R, Cutler AJ, Gazda T, Ketter TA, Keck PE, et al. Extended-release carbamazepine capsules as monotherapy in bipolar disorder : pooled results from two randomised, double-blind, placebo-controlled trials. CNS Drugs 2006;20:219-231. https://doi.org/10.2165/00023210-200620030-00004
  45. Stahl S, Lombardo I, Loebel A, Mandel FS. Efficacy of ziprasidone in dysphoric mania: pooled analysis of two double-blind studies. J Affect Disord 2010;122:39-45. https://doi.org/10.1016/j.jad.2009.06.023
  46. Swann AC, Bowden CL, Morris D, Calabrese JR, Petty F, Small J, et al. Depression during mania. Treatment response to lithium or divalproex. Arch Gen Psychiatry 1997;54:37-42. https://doi.org/10.1001/archpsyc.1997.01830130041008
  47. Weisler RH, Kalali AH, Ketter TA; SPD417 Study Group. A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry 2004;65:478-484. https://doi.org/10.4088/JCP.v65n0405
  48. Vieta E, Ramey T, Keller D, English PA, Loebel AD, Miceli J. Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study. J Psychopharmacol 2010;24:547-558. https://doi.org/10.1177/0269881108099418
  49. Zhang ZJ, Kang WH, Tan QR, Li Q, Gao CG, Zhang FG, et al. Adjunctive herbal medicine with carbamazepine for bipolar disorders: A double-blind, randomized, placebo-controlled study. J Psychiatr Res 2007;41:360-369. https://doi.org/10.1016/j.jpsychires.2005.06.002
  50. Selle V, Schalkwijk S, Vazquez GH, Baldessarini RJ. Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics. Pharmacopsychiatry 2014;47: 43-52. https://doi.org/10.1055/s-0033-1363258
  51. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002;59:530-537. https://doi.org/10.1001/archpsyc.59.6.530
  52. Okuma T, Yamashita I, Takahashi R, Itoh H, Otsuki S, Watanabe S, et al. Comparison of the antimanic efficacy of carbamazepine and lithium carbonate by double-blind controlled study. Pharmacopsychiatry 1990;23:143-150. https://doi.org/10.1055/s-2007-1014497
  53. Small JG, Klapper MH, Milstein V, Kellams JJ, Miller MJ, Marhenke JD, et al. Carbamazepine compared with lithium in the treatment of mania. Arch Gen Psychiatry 1991;48:915-921. https://doi.org/10.1001/archpsyc.1991.01810340047006
  54. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010;123:225-233. https://doi.org/10.1016/j.schres.2010.07.012
  55. de Bartolomeis A, Perugi G. Combination of aripiprazole with mood stabilizers for the treatment of bipolar disorder: from acute mania to long-term maintenance. Expert Opin Pharmacother 2012;13:2027-2036. https://doi.org/10.1517/14656566.2012.719876
  56. Pacchiarotti I, Bond DJ, Baldessarini RJ, Nolen WA, Grunze H, Licht RW, et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry 2013;170:1249-1262. https://doi.org/10.1176/appi.ajp.2013.13020185
  57. Montejo AL, Arango C, Bernardo M, Carrasco JL, Crespo-Facorro B, Cruz JJ, et al. Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics. Front Neuroendocrinol 2017;45:25-34. https://doi.org/10.1016/j.yfrne.2017.02.003
  58. Lorberg B, Youssef NA, Bhagwagar Z. Lamotrigine-associated rash: to rechallenge or not to rechallenge? Int J Neuropsychopharmacol 2009;12:257-265. https://doi.org/10.1017/S1461145708009504
  59. Seo HJ, Chiesa A, Lee SJ, Patkar AA, Han C, Masand PS, et al. Safety and tolerability of lamotrigine: results from 12 placebo-controlled clinical trials and clinical implications. Clin Neuropharmacol 2011;34:39-47. https://doi.org/10.1097/WNF.0b013e3182055c07
  60. Dols A, Beekman A. Older age bipolar disorder. Psychiatr Clin North Am 2018;41:95-110. https://doi.org/10.1016/j.psc.2017.10.008
  61. Chen P, Dols A, Rej S, Sajatovic M. Update on the epidemiology, diagnosis, and treatment of mania in older-age bipolar disorder. Curr Psychiatry Rep 2017;19:46. https://doi.org/10.1007/s11920-017-0804-8
  62. Orsolini L, Tomasetti C, Valchera A, Vecchiotti R, Matarazzo I, Vellante F, et al. An update of safety of clinically used atypical antipsychotics. Expert Opin Drug Saf 2016;15:1329-1347. https://doi.org/10.1080/14740338.2016.1201475
  63. Stepanova E, Findling RL. Psychopharmacology of bipolar disorders in children and adolescents. Pediatr Clin North Am 2017;64:1209-1222. https://doi.org/10.1016/j.pcl.2017.08.002

Cited by

  1. Korean Medication Algorithm for Bipolar Disorder 2018: Comparisons with Other Treatment Guidelines vol.17, pp.2, 2018, https://doi.org/10.9758/cpn.2019.17.2.155
  2. Lithium and the Woozle effect vol.21, pp.4, 2019, https://doi.org/10.1111/bdi.12753
  3. Lithium Prescribing and Therapeutic Drug Monitoring in Bipolar Disorder: A Survey of Current Practices and Perspectives vol.26, pp.5, 2018, https://doi.org/10.1097/pra.0000000000000493
  4. Clinical correlates associated with the long-term response of bipolar disorder patients to lithium, valproate or lamotrigine: A retrospective study vol.15, pp.1, 2018, https://doi.org/10.1371/journal.pone.0227217
  5. The Korean Medication Algorithm Project for Bipolar Disorder (KMAP‐BP): Changes in preferred treatment strategies and medications over 16 years and five editions vol.22, pp.5, 2018, https://doi.org/10.1111/bdi.12902
  6. 노년기 정신장애의 전기경련치료 vol.27, pp.2, 2018, https://doi.org/10.22857/kjbp.2020.27.2.002
  7. 자살 위험성 및 자살 시도 방지에 대한 전기경련치료의 역할 vol.27, pp.2, 2018, https://doi.org/10.22857/kjbp.2020.27.2.004
  8. Pharmacological management of bipolar disorder: Japanese expert consensus vol.22, pp.8, 2018, https://doi.org/10.1111/bdi.12959
  9. Lithium treatment of Bipolar disorder in adults: A systematic review of randomized trials and meta-analyses vol.54, pp.None, 2022, https://doi.org/10.1016/j.euroneuro.2021.10.003
  10. What not to use in bipolar disorders: A systematic review of non-recommended treatments in clinical practice guidelines vol.298, pp.no.pa, 2018, https://doi.org/10.1016/j.jad.2021.11.007